Urothelial Cancer | Specialty

Revisit Every OncLive On Air Episode From May 2025

May 30th 2025

Read a recap of the episodes of OncLive On Air that debuted in May 2025.

FDA Approval Insights: Perioperative Durvalumab Plus Chemo in MIBC: With Matthew Galsky, MD

May 28th 2025

Dr Galsky discusses the FDA approval of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab monotherapy for MIBC.

CHMP Recommends EU Approval of Perioperative Durvalumab for Muscle-Invasive Bladder Cancer

May 27th 2025

CHMP backed perioperative durvalumab plus neoadjuvant chemotherapy for MIBC based on the NIAGARA trial, which showed improved EFS vs chemotherapy alone.

The OncFive: Top Oncology Articles for the Week of 5/18

May 24th 2025

FDA’s ODAC voted on therapeutic approaches in lymphoma, bladder, prostate, and myeloma, and more from OncLive this week.

FDA’s ODAC Votes Against Risk/Benefit Profile of UGN-102 in Recurrent, Low-Grade, Intermediate-Risk NMIBC

May 21st 2025

The FDA’s ODAC voted against the risk/benefit profile of UGN-102 for recurrent, low-grade, intermediate-risk non–muscle-invasive bladder cancer.

The ‘Bar Is High’ to Usurp BCG, but Novel Therapies Could Drive Change in Bladder Cancer Management

May 20th 2025

Bogdana Schmidt, MD, MPH, discussed FDA-approved BCG-refractory treatments and recent shifts in BCG-naive NMIBC management.

FDA Approval of Perioperative Durvalumab Plus Chemo Supports the Efficacy of a Novel MIBC Management Approach

May 19th 2025

Matthew Galsky, MD, discusses the significance of the FDA approval of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in MIBC.

Dr Vlachou on the Rationale for Evaluating Perioperative Enfortumab Vedotin Plus Pembrolizumab in Upper Tract Urothelial CancerCancer

May 16th 2025

Evangelia Vlachou, MD, discusses the investigation of enfortumab vedotin plus pembrolizumab as perioperative therapy in upper tract urothelial cancer.

Dr Schmidt on the Development of Novel Treatment Delivery Approaches in Bladder Cancer

May 13th 2025

Bogdana Schmidt, MD, MPH, details the emergence of novel treatment delivery methods in bladder cancer.

BCG Shortage Warrants Treatment Shifts, New Treatment Strategies in Bladder Cancer

May 13th 2025

Bogdana Schmidt, MD, MPH, details the role of BCG in bladder cancer and navigating BCG shortages across the board during Bladder Cancer Awareness Month.

Frontline Disitamab Vedotin Plus Toripalimab Improves PFS and OS in HER2+ Metastatic Urothelial Carcinoma

May 12th 2025

Disitamab vedotin plus toripalimab improved PFS and OS vs chemotherapy in HER2-expressing metastatic urothelial carcinoma.

The OncFive: Top Oncology Articles for the Week of 5/4

May 10th 2025

A doublet is approved for KRAS-mutated ovarian cancer, T-DXd followed by THP improves pCR rates in HER2+ breast cancer, and more from OncLive.

Durvalumab Plus BCG Improves DFS in High-Risk Non–Muscle-Invasive Bladder Cancer

May 9th 2025

Durvalumab plus BCG induction and maintenance improved DFS vs BCG in these settings alone in patients with high-risk non–muscle-invasive bladder cancer.

Dr Grivas on Incorporating Perioperative Durvalumab Plus Neoadjuvant Chemo into MIBC Management

May 7th 2025

Petros Grivas, MD, PhD, details questions and considerations for integrating perioperative durvalumab plus neoadjuvant chemotherapy into MIBC management.

Contrasting Adjuvant and Perioperative Trial Designs Help Refine MIBC Management

May 7th 2025

Petros Grivas, MD, PhD, discusses data from CheckMate 274 and how emerging data from bladder cancer trials are shaping immunotherapy strategies in MIBC.

Dr Schmidt on FDA-Approved Bladder-Sparing Therapies in BCG-Refractory NMIBC

May 6th 2025

Bogdana Schmidt, MD, MPH, highlights FDA approved bladder-sparing therapies for patients with BCG-refractory non–muscle-invasive bladder cancer.

NIAGARA Trial Validates Perioperative Durvalumab Approach in MIBC

May 6th 2025

Petros Grivas, MD, PhD, discusses key findings from the NIAGARA trial and how these data support the use of perioperative durvalumab in MIBC management.

FDA Issues Refusal to File Letter for Nogapendekin Alfa Inbakicept sBLA in BCG-Unresponsive Papillary NMIBC

May 5th 2025

A meeting has been requested to address the FDA's refusal to file an sBLA for nogapendekin alfa inbakicept plus BCG in BCG-unresponsive papillary NMIBC.

Five Under 5: Top Oncology Videos for the Week of 4/27

May 4th 2025

The top 5 OncLive videos of the week cover insights in colorectal cancer, prostate cancer, myeloma, renal cell carcinoma, and urothelial carcinoma.

Real-World Data Support Nadofaragene Firadenovec Use in BCG-Unresponsive NMIBC: With Jacob Moyer, BS; and Mark D. Tyson, II, MD, MPH

May 1st 2025